Life Sciences AISeedWorkflowℹ161 viewsProxima Bio
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Company snapshot
- Stage
- Seed
- Funding
- Seed · $80M · Jan 1, 2026
- Status
- published
- Updated
- Nov 4, 2026
- Views
- 161 views
- Category
- Life Sciences AI
- Website
- proximabio.com
What they're building
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Founders
Zachary Carpenter
Co-founder & CEO
Luca Naef
Co-founder & CTO
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Agentic loops, Multimodal processing
- Estimated model demand
- High intensity
NYC footprint
- NYC presence
- NYC company or team supported by public sources. Street address has not been verified.
Funding
Latest funding: Seed · $80M · Jan 1, 2026. Total raised: $80M. Lead investor: DCVC.
AI Lab Fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Current AI product, canonical identity, active operations and NYC presence. Funding not rechecked unless a linked funding correction is recorded.
Notes
Proxima Bio is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.
Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.
Life Sciences AIInfraℹRecent Activity
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Life Sciences AIWorkflowℹRecent Activity
The physical execution layer for autonomous science.
Opentrons connects AI models to open laboratory robots, turning experiment design, execution, and structured results into a continuous learning loop for autonomous science.
Life Sciences AIInfraℹRecent Activity